Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Welcome and Introduction to Vi3C

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Feb

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Welcome and Introduction to Vi3C

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Stage II Melanoma Adjuvant Pembrolizumab and Risk of New Skin Cancers

Long-Term Survival Results With Addition of Adjuvant mFOLFOX6 to Hepatectomy in Patients With Liver Metastases From Colorectal Cancer

Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO

High Response Rates With Front-Line Pivekimab Sunirine in BPDCN

Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology